Skip to main content

MINI REVIEW article

Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders: Autoinflammatory Disorders
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1502855
This article is part of the Research Topic The Mechanisms and Interplay of cell death in rheumatoid arthritis, lupus, and scleroderma View all 8 articles

PANoptosis in Autoimmune Diseases Interplay Between Apoptosis, Necrosis, and Pyroptosis

Provisionally accepted
Kangnan Liu Kangnan Liu 1*Mi Wang Mi Wang 2Dongdong Li Dongdong Li 3*Nguyen T. Duc Duong Nguyen T. Duc Duong 1*Yawei Liu Yawei Liu 2*Junfu Ma Junfu Ma 4*Kai Xin Kai Xin 2*Zipeng Zhou Zipeng Zhou 5*
  • 1 School of Osteopathy, Henan University of Chinese Medicine,, Zhengzhou, China
  • 2 Rheumatology Department, The Third Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan Province, China
  • 3 Oncology Department, Henan Province Hospital of Chinese Medicine, Zhengzhou, China
  • 4 Rheumatology Department, Henan Province Hospital of Chinese Medicine(The Second Affiliated Hospital of Henan University of Chinese Medicine), Zhengzhou, Henan Province, China
  • 5 Henan Province Hospital of Traditional Chinese Medicine, Zhengzhou, China

The final, formatted version of the article will be published soon.

    PANoptosis is a newly identified inflammatory programmed cell death (PCD) that involves the interplay of apoptosis, necrosis, and pyroptosis. However, its overall biological effects cannot be attributed to any one type of PCD alone.PANoptosis is regulated by a signaling cascade triggered by the recognition of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) by various sensors.This triggers the assembly of the PANoptosome, which integrates key components from other PCD pathways via adapters and ultimately activates downstream execution molecules, resulting in cell death with necrotic, apoptotic, and pyroptotic features.Autoimmune diseases are characterized by reduced immune tolerance to self-antigens, leading to abnormal immune responses, often accompanied by systemic chronic inflammation. Consequently, PANoptosis, as a unique innate immune-inflammatory PCD pathway, has significant pathophysiological relevance to inflammation and autoimmunity.However, most previous research on PANoptosis has focused on tumors and infectious diseases, leaving its activation and role in autoimmune diseases unclear. This review briefly outlines the characteristics of PANoptosis and summarizes several newly identified PANoptosome complexes, their activation mechanisms, and key components. We also explored the dual role of PANoptosis in diseases and potential therapeutic approaches targeting PANoptosis. Additionally, we review the existing evidence for PANoptosis in several autoimmune diseases and explore the potential regulatory mechanisms involved.

    Keywords: PANoptosis, PANoptosome, Apoptosis, Necrosis, pyroptosis, Autoimmune Diseases

    Received: 27 Sep 2024; Accepted: 14 Oct 2024.

    Copyright: © 2024 Liu, Wang, Li, Duc Duong, Liu, Ma, Xin and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Kangnan Liu, School of Osteopathy, Henan University of Chinese Medicine,, Zhengzhou, China
    Dongdong Li, Oncology Department, Henan Province Hospital of Chinese Medicine, Zhengzhou, China
    Nguyen T. Duc Duong, School of Osteopathy, Henan University of Chinese Medicine,, Zhengzhou, China
    Yawei Liu, Rheumatology Department, The Third Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan Province, China
    Junfu Ma, Rheumatology Department, Henan Province Hospital of Chinese Medicine(The Second Affiliated Hospital of Henan University of Chinese Medicine), Zhengzhou, Henan Province, China
    Kai Xin, Rheumatology Department, The Third Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan Province, China
    Zipeng Zhou, Henan Province Hospital of Traditional Chinese Medicine, Zhengzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.